Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial.

Next Previous
Trial Profile

Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Naproxen
  • Indications Axial spondyloarthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms INFAST
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 13 Jul 2016 Results of a post-hoc analysis published in the Rheumatology
    • 25 Mar 2016 Results published in the Arthritis and Rheumatology
    • 13 Jun 2015 Results (part I)presented at the 16th Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top